Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Pediatr Neurol. 2022 Jan:126:43-45. doi: 10.1016/j.pediatrneurol.2021.10.006. Epub 2021 Oct 13.

Authors

Alexandra B Kornbluh¹, Grant T Liu², Sarah E Hopkins³

Affiliations

¹ Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: alliekornbluh@gmail.com.
² Division of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
³ Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

PMID: 34736062
DOI: 10.1016/j.pediatrneurol.2021.10.006

No abstract available

Keywords: MOG; Optic neuritis; Outcomes; Pediatric.

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Humans
Immunologic Factors / administration & dosage*
Male
Myelin-Oligodendrocyte Glycoprotein / immunology*
Optic Neuritis / complications
Optic Neuritis / drug therapy
Optic Neuritis / immunology
Optic Neuritis / physiopathology*
Vision Disorders / drug therapy
Vision Disorders / etiology
Vision Disorders / physiopathology*

Substances

Immunologic Factors
MOG protein, human
Myelin-Oligodendrocyte Glycoprotein